Publications (85) JOSE IGNACIO RODRÍGUEZ BARBOSA publications

filter_list

2025

  1. A bioactive soluble recombinant mouse LIGHT promotes effective tumor immune cell infiltration delaying tumor growth

    Journal of Molecular Medicine

2024

  1. Comparative Analysis of the Health Status of Heart Transplant Patients with Different Levels of Physical Activity

    Applied Sciences (Switzerland), Vol. 14, Núm. 18

2023

  1. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression

    Frontiers in Immunology, Vol. 14

2022

  1. Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib

    Scientific Reports, Vol. 12, Núm. 1

  2. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance

    Frontiers in Immunology, Vol. 13

  3. The Role of the Inhibitory Ligand HVEM and Its Receptors CD160 and BTLA in the Regulation of Anti-retroviral T Cell Responses

    Frontiers in Virology, Vol. 2

  4. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection

    Translational Research, Vol. 239, pp. 103-123

2021

  1. Calidad de vida del receptor de un órgano sólido en Castilla y León

    Revista ROL de enfermería, Vol. 44, Núm. 5, pp. 12-20

  2. Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases

    Frontiers in Immunology

2020

  1. Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model

    Cancer Immunology, Immunotherapy, Vol. 69, Núm. 6, pp. 1001-1014

  2. The role of TNFR2 and DR3 in the in vivo expansion of tregs in t cell depleting transplantation regimens

    International Journal of Molecular Sciences, Vol. 21, Núm. 9

2019

  1. CD160 serves as a negative regulator of NKT cells in acute hepatic injury

    Nature Communications, Vol. 10, Núm. 1

  2. Correction to: T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway (Cellular and Molecular Immunology, (2017), 14, 6, (497-510), 10.1038/cmi.2015.101)

    Cellular and Molecular Immunology

  3. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT

    Cellular and Molecular Immunology, Vol. 16, Núm. 7, pp. 679-682

2018

  1. Descripción de la calidad de vida de los pacientes con trasplante renal del Principado de Asturias

    Tiempos de enfermería y salud = Nursing and health times, Núm. 4, pp. 20-24

  2. Downregulation of BTLA on NKT cells promotes tumor immune control in a mouse model of mammary Carcinoma

    International Journal of Molecular Sciences, Vol. 19, Núm. 3

  3. Therapeutic implications of NK cell regulation of allogeneic CD8 T cell-mediated immune responses stimulated through the direct pathway of antigen presentation in transplantation

    mAbs, Vol. 10, Núm. 7, pp. 1030-1044

2017

  1. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier

    Translational Research, Vol. 181, pp. 83-95.e3

  2. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway

    Cellular and Molecular Immunology, Vol. 14, Núm. 6, pp. 497-510

2016

  1. Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells

    mAbs, Vol. 8, Núm. 3, pp. 478-490